Economic analysis of Neoral in de novo renal transplant patients in Canada.

@article{Kingma1997EconomicAO,
  title={Economic analysis of Neoral in de novo renal transplant patients in Canada.},
  author={I Kingma and David Ludwin and Raymond Dandavino and Jennifer L. Wolff and Rolf Loertscher and L Beauregard-Zollinger and P. Bacquet and Serge Boucher and Marc Rivi{\`e}re},
  journal={Clinical transplantation},
  year={1997},
  volume={11 1},
  pages={42-8}
}
This pilot economic evaluation was performed as part of the Canadian arm of an international randomized, controlled, double-blind safety and tolerability trial (OLM-105/NOF-2). The clinical study compared the safety and tolerability of a new microemulsion oral formulation of cyclosporine A (Neoral) with the oral cyclosporine. A preparation currently in use (Sandimmune SGC)/(SGC). To assess the economic impact of Neoral in newly grafted renal transplant patients, primary cost data were collected… CONTINUE READING

From This Paper

Topics from this paper.
3 Citations
1 References
Similar Papers

Citations

Publications citing this paper.

References

Publications referenced by this paper.

Economic analysis of Neoral in de novo renal transplant patients in Canada

  • P Bacquet

Similar Papers

Loading similar papers…